The autopsy results from 2016 were striking enough: human brain tissue already laden with thousands of microplastic particles per gram. But the samples from 2024 showed something more alarming. Researchers analyzing postmortem tissue found that brain microplastic concentrations had risen by roughly 50 percent in just eight years [3]. That rise, from a median of 3,345 micrograms per gram to 4,917, reflects something happening in real time: every person alive today is now a storage vessel for plastic contamination that science is only beginning to understand.
On April 2, 2026, the EPA and HHS tried to formalize that understanding into policy. The agencies announced at EPA headquarters that microplastics would be added to the draft Sixth Contaminant Candidate List, a milestone marking the first time the federal drinking water program had identified microplastics as a priority group warranting regulatory attention [1]. The same day, HHS Secretary Robert F. Kennedy Jr. announced STOMP, a five-year, $144 million program through the Advanced Research Projects Agency for Health designed to measure microplastics in human tissue, identify which particles pose the greatest threat, and develop methods to remove them from the body [1]. These announcements represent an unusual degree of federal urgency around a contaminant for which the causal chain to disease remains, in key respects, unresolved.
What the Tissue Tells Us
The most direct evidence that microplastics are not just present but embedded in human biology comes from a series of studies examining actual tissue. The highest-profile contribution came in March 2024, when researchers published findings in the New England Journal of Medicine showing, for the first time, a statistical association between microplastics found in artery plaque and adverse cardiovascular outcomes [2]. The study followed patients who had undergone surgery to remove plaque from their arteries. More than two years after the procedure, those whose excised plaque contained measurable microplastics showed a higher rate of heart attack, stroke, and death compared to patients whose plaque was plastic-free [2]. The researchers used pyrolysis chromatography mass spectrometry to identify the particles, a method that rules out contamination during sample handling.
That finding landed in a major journal and generated significant media coverage. But the study had important limitations. It was observational, not interventional. The researchers could establish that microplastics were present in the plaque and that outcomes were worse, but they could not prove the particles caused those outcomes. It is possible, as several researchers noted at the time, that inflammation driven by some other factor allows microplastics to accumulate in vessel walls as a secondary consequence. The NEJM paper itself used careful language: microplastics were "emerging as a potential risk factor" based on preclinical studies [2].
The brain tissue studies tell a similar story, with added complexity. Research published in Nature Medicine in 2025 found that brain samples from 2024 contained substantially higher MNP concentrations than liver or kidney tissue from the same donors, with a median of 4,917 micrograms per gram in brain versus roughly 400 micrograms per gram in the other organs [3]. Brain tissue also contained a higher proportion of polyethylene, the most common plastic polymer, averaging 75 percent of detected particles [3]. The study also reported that dementia patients showed higher concentrations than non-dementia patients, a finding that has since become one of the most cited data points in public discussions of microplastic health effects. That association is real, but it is not yet resolved. Higher concentrations in people with cognitive decline could reflect decades of accumulation as a downstream consequence of the disease process; they could be a contributing cause; or some third variable could drive both [3]. The authors did not claim to have answered that question.
How the Particles Get In
Understanding risk requires understanding exposure. A review published in Current Environmental Health Reports in 2026 laid out what is known about pathways, and the picture is broader than most public discussions suggest [4].
Ingestion remains the dominant route. Microplastics have been detected in food products including seafood, sea salt, and honey; in bottled water; and in tap water supplied from both surface and groundwater sources [4]. The commonly cited figure is that adults consume approximately five grams of microplastics per week, roughly the weight of a credit card, though that estimate carries significant uncertainty [4]. Inhalation is a secondary but significant pathway. Synthetic clothing, household dust, and urban air all contain microplastic fibers that can reach the lower respiratory tract [4]. Dermal absorption through intact skin appears to be minimal, though absorption through hair follicles and sweat glands has been detected in laboratory conditions [4].
What makes these pathways difficult to model is that microplastics do not behave like a single contaminant. They vary by polymer type, particle size, shape, and the chemical additives attached to their surfaces. A fragment of polyethylene from a water bottle is not the same as a fiber from a synthetic fleece, and the body responds differently to each. The smaller the particle, the more likely it is to cross biological barriers. Nanoplastics, defined as particles below one micron, have been detected in lung tissue, placental tissue, testicular tissue, semen, blood, and breast milk [4]. The detection of these particles inside fetal and reproductive tissue is, several researchers have noted, among the more troubling findings in the field.
The Uncertainty Problem
Here is the tension that makes covering this topic difficult: the accumulation is not hypothetical. Microplastics are in human brains, hearts, blood, and testicles. The question of what they are doing there is not a fringe hypothesis. It is the central scientific question of the field, and it is one that the current evidence base cannot fully answer.
Animal studies have documented effects including reproductive toxicity, metabolic disruption, neurotoxicity, and immune activation [4]. These findings are not trivial, but they do not translate directly to humans. Dose matters, and animal studies often use exposure levels higher than what humans encounter in daily life. The mechanisms are also contested: some research suggests inflammation-driven effects, while other work points to direct cellular uptake of particles [4]. The cardiovascular NEJM study represented a genuine step forward in human evidence, but a single observational study in one patient population does not establish causation, and the confidence intervals around the risk estimates were wide.
This is not a reason to dismiss the concern. It is a reason to be precise about what the evidence shows. The EPA's inclusion of microplastics on the Contaminant Candidate List does not constitute regulation; it signals that a substance warrants serious attention and future regulatory consideration [1]. The CCL 6 list also includes pharmaceuticals as a group, PFAS, disinfection byproducts, 75 individual chemicals, and nine microbes [1]. The public comment period runs until November 17, 2026 [1]. STOMP's three-pronged approach, combining measurement technology with target identification and removal method development, represents a serious research infrastructure commitment [1].
What remains unknown is substantial. There are no established safe exposure thresholds. There are no long-term cohort studies tracking health outcomes in people with measured microplastic burdens. There are no human intervention trials. The brain concentration data from 2016 to 2024 shows a clear increase, but whether that trend continues, plateaus, or produces measurable cognitive effects at the population level is not yet knowable. Whether the particles identified in artery plaque are a cause of cardiovascular disease, a marker of it, or neither remains an open question.
The Research Gap and the Federal Response
The announcement at EPA headquarters brought together researchers including Dr. Marcus Eriksen, Matthew Campen, and Leonardo Trasande, scientists who have spent years documenting microplastic presence in human tissue and arguing for increased federal attention [1]. Their presence alongside EPA Administrator Lee Zeldin and Secretary Kennedy reflected a rare alignment between academic research communities and regulatory decision-makers.
Whether that alignment produces enforceable standards within a decade, or whether it stalls at the research phase as other contaminants have, is a political question as much as a scientific one. What the current evidence does not support is complacency. The tissue data is not ambiguous about accumulation. The questions are about harm, and harm questions take time, money, and large cohort studies to answer. STOMP is designed to provide some of that infrastructure, but five years and $144 million will not close every gap. What they may do is establish whether the particles in human organs are passengers or drivers.
The honest answer, based on what is known, is that the science has not yet settled the most important questions about microplastic health effects. That uncertainty is not the same as reassurance. It is a map of what remains to be studied, and it is extensive.